• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines

tetano

Editor, Senior Moderator
NPJ Vaccines. 2017 Dec 15;2:35. doi: 10.1038/s41541-017-0036-2. eCollection 2017.
[h=1]Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines.[/h] Sutton TC[SUP]1[/SUP], Chakraborty S[SUP]#[/SUP][SUP]2[/SUP], Mallajosyula VVA[SUP]#[/SUP][SUP]2[/SUP], Lamirande EW[SUP]1[/SUP], Ganti K[SUP]1[/SUP], Bock KW[SUP]3[/SUP], Moore IN[SUP]3[/SUP], Varadarajan R[SUP]2[/SUP], Subbarao K[SUP]1,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The stem of the influenza A virus hemagglutinin (HA) is highly conserved and represents an attractive target for a universal influenza vaccine. The 18 HA subtypes of influenza A are phylogenetically divided into two groups, and while protection with group 1 HA stem vaccines has been demonstrated in animal models, studies on group 2 stem vaccines are limited. Thus, we engineered group 2 HA stem-immunogen (SI) vaccines targeting the epitope for the broadly neutralizing monoclonal antibody CR9114 and evaluated vaccine efficacy in mice and ferrets. Immunization induced antibodies that bound to recombinant HA protein and viral particles, and competed with CR9114 for binding to the HA stem. Mice vaccinated with H3 and H7-SI were protected from lethal homologous challenge with X-79 (H3N2) or A/Anhui/1/2013 (H7N9), and displayed moderate heterologous protection. In ferrets, H7-SI vaccination did not significantly reduce weight loss or nasal wash titers after robust 10[SUP]7[/SUP] TCID[SUB]50[/SUB] H7N9 virus challenge. Epitope mapping revealed ferrets developed lower titers of antibodies that bound a narrow range of HA stem epitopes compared to mice, and this likely explains the lower efficacy in ferrets. Collectively, these findings indicate that while group 2 SI vaccines show promise, their immunogenicity and efficacy are reduced in larger outbred species, and will have to be enhanced for successful translation to a universal vaccine.


PMID: 29263889 PMCID: PMC5732283 DOI: 10.1038/s41541-017-0036-2
 
Back
Top Bottom